Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Roche Holding AG (RO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
375.20 -2.60    -0.69%
11:31:00 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012032113 
VALOR:  1203211
  • Volume: 60,152
  • Bid/Ask: 374.20 / 375.20
  • Day's Range: 369.00 - 376.40
Roche Holding 375.20 -2.60 -0.69%
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM 20.57 19.2
Price to Sales TTM 4.37 4.44
Price to Cash Flow MRQ 33.48 37.43
Price to Free Cash Flow TTM 33.48 37.28
Price to Book MRQ 10.88 9.35
Price to Tangible Book MRQ 175.47 150.55
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 69.19% 69.45
Gross Margin 5YA 71.04% 70.78
Operating margin TTM 28.91% 27.08
Operating margin 5YA 28.01% 26.44
Pretax margin TTM 27.7% 32.66
Pretax margin 5YA 26.77% 26.92
Net Profit margin TTM 23.78% 28.73
Net Profit margin 5YA 21.82% 22.34
   
Revenue/Share TTM 73.02 60.09
Basic EPS ANN 16.39 14.63
Diluted EPS ANN 16.2 14.47
Book Value/Share MRQ 30.6 30.29
Tangible Book Value/Share MRQ 1.95 2.11
Cash/Share MRQ 16.28 15.18
Cash Flow/Share TTM 22.53 19.87
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM 45.8% 43.4
Return on Equity 5YA 41.35% 35.12
Return on Assets TTM 16.74% 16.93
Return on Assets 5YA 15.62% 13.86
Return on Investment TTM 27.82% 26.65
Return on Investment 5YA 23.77% 20.56
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ -0.76% 161.54
EPS(TTM) vs TTM 1 Yr. Ago TTM -2% 46.81
5 Year EPS Growth 5YA 7.78% 13.1
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 10.49% 8.95
Sales (TTM) vs TTM 1 Yr. Ago TTM 7.68% 7.25
5 Year Sales Growth 5YA 4.42% 3.75
5 Year Capital Spending Growth 5YA -1.99% -1.29
   
Quick Ratio MRQ 0.73 0.89
Current Ratio MRQ 0.93 1.1
LT Debt to Equity MRQ 65.65% 57.76
Total Debt to Equity MRQ 127.4% 106.4
Efficiency    
Asset Turnover TTM 0.7 0.63
Inventory Turnover TTM 2.6 2.5
Revenue/Employee TTM 622.29K 587.18K
Net Income/Employee TTM 147.99K 162.07K
Receivable Turnover TTM 5.99 6.08
   
Dividend Yield ANN 2.79% 2.96
Dividend Yield 5 Year Avg. 5YA 2.98% 2.95
Dividend Growth Rate ANN 2.25% 2.21
Payout Ratio TTM 54.03% 48.81
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Ruta Rublevska
Ruta Rublevska Nov 16, 2020 3:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just like Biolidics. they get approval for Covid19 tests kits in USA
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is the historical price adjusted for stock splits?
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email